Phosphodiesterase 5 inhibitors for pulmonary hypertension

Source:
Cochrane Database of Systematic Reviews
Publisher:
Cochrane Database of Systematic Reviews
Publication date:
31 January 2019

Abstract

Review of 36 studies (n=2999) found PDE5 inhibitors (PDEi’s) appear to have beneficial effects in group 1 pulmonary hypertension, and sildenafil/ tadalafil/vardenafil are all efficacious. Side-effect profile should be considered for each patient when selecting a PDE5 inhibitor.